Elena Bennati1, Francesca Girolami2, Gaia Spaziani2, Giovanni Battista Calabri2, Claudio Favre3, Iris Parrini4, Fabiana Lucà5, Angela Tamburini3, Silvia Favilli2. 1. Pediatric Cardiology Unit, Meyer Children's Hospital, Viale G. Pieraccini 24, Florence, Italy. elena.bennati@meyer.it. 2. Pediatric Cardiology Unit, Meyer Children's Hospital, Viale G. Pieraccini 24, Florence, Italy. 3. Department of Pediatric Hematology-Oncology, Meyer Children's Hospital, Viale G. Pieraccini 24, Florence, Italy. 4. Cardiology Unit, Mauriziano Umberto I Hospital, Corso Turati 62, Turin, Italy. 5. Department of Cardiology, Grande Ospedale Metropolitano, Azienda Ospedaliera Bianchi Melacrino Morelli, Reggio Calabria, Italy.
Abstract
PURPOSE OF REVIEW: Cardio-oncology is an increasingly important field of cardiology that focuses on the detection, monitoring, and treatment of cardiovascular disease (CVD) occurring during and after oncological treatments. The survival rate for childhood cancer patients has dramatically increased thanks to new treatment protocols and cardiovascular (CV) sequelae represent the third most frequent cause of mortality in surviving patients. This study aims to provide a complete and updated review of all the main aspects of cardio-oncology in childhood and to highlight the critical issues. RECENT FINDINGS: The problem of CV complications in childhood cancer survivors raises the need to make an early diagnosis of cardiotoxicity by the new imaging and laboratory techniques in order to intervene promptly and to implement pharmacological strategies and lifestyle changes to reduce or even to prevent cardiac injury. Furthermore, a stratification of CV risk, also including new predisposing factors such as the presence of some genetic mutations, is of paramount importance before undertaking oncological treatments. Besides, a systematic and personalized planning of long-term follow-up is fundamental to ensure a transition from pediatric to adult hospital and to avoid missed or late diagnosis of cardiomyopathy. We reviewed the main risk factors for cardiotoxicity in children, both traditional and emerging ones: the mechanisms of toxicity of both old and new antineoplastic therapies, the techniques for detecting cardiac damage, and the current evidence regarding pharmacological cardioprotection. At the end, we focused our attention on the existing guidelines and strategies about the long-term follow-up of childhood cancer survivors.
PURPOSE OF REVIEW: Cardio-oncology is an increasingly important field of cardiology that focuses on the detection, monitoring, and treatment of cardiovascular disease (CVD) occurring during and after oncological treatments. The survival rate for childhood cancer patients has dramatically increased thanks to new treatment protocols and cardiovascular (CV) sequelae represent the third most frequent cause of mortality in surviving patients. This study aims to provide a complete and updated review of all the main aspects of cardio-oncology in childhood and to highlight the critical issues. RECENT FINDINGS: The problem of CV complications in childhood cancer survivors raises the need to make an early diagnosis of cardiotoxicity by the new imaging and laboratory techniques in order to intervene promptly and to implement pharmacological strategies and lifestyle changes to reduce or even to prevent cardiac injury. Furthermore, a stratification of CV risk, also including new predisposing factors such as the presence of some genetic mutations, is of paramount importance before undertaking oncological treatments. Besides, a systematic and personalized planning of long-term follow-up is fundamental to ensure a transition from pediatric to adult hospital and to avoid missed or late diagnosis of cardiomyopathy. We reviewed the main risk factors for cardiotoxicity in children, both traditional and emerging ones: the mechanisms of toxicity of both old and new antineoplastic therapies, the techniques for detecting cardiac damage, and the current evidence regarding pharmacological cardioprotection. At the end, we focused our attention on the existing guidelines and strategies about the long-term follow-up of childhood cancer survivors.
Authors: Maarten P van den Berg; Karin Y van Spaendonck-Zwarts; Dirk J van Veldhuisen; Jourik A Gietema; Aleida Postma; J Peter van Tintelen Journal: Eur J Heart Fail Date: 2010-10-16 Impact factor: 15.534
Authors: Neha Bansal; Javier G Blanco; Umesh C Sharma; Saraswati Pokharel; Shannon Shisler; Steven E Lipshultz Journal: Cancer Metastasis Rev Date: 2020-03 Impact factor: 9.264
Authors: Joseph R Carver; Charles L Shapiro; Andrea Ng; Linda Jacobs; Cindy Schwartz; Katherine S Virgo; Karen L Hagerty; Mark R Somerfield; David J Vaughn Journal: J Clin Oncol Date: 2007-06-18 Impact factor: 44.544
Authors: Folefac Aminkeng; Colin J D Ross; Shahrad R Rassekh; Soomi Hwang; Michael J Rieder; Amit P Bhavsar; Anne Smith; Shubhayan Sanatani; Karen A Gelmon; Daniel Bernstein; Michael R Hayden; Ursula Amstutz; Bruce C Carleton Journal: Br J Clin Pharmacol Date: 2016-06-30 Impact factor: 4.335
Authors: Gazala Hitawala; Esha Jain; Lisett Castellanos; Radhika Garimella; Radhika Akku; Adila K Chamavaliyathil; Huma Irfan; Vikash Jaiswal; Jonathan Quinonez; Maher Dakroub; Muhammad Hanif; Ali H Baloch; Ivan S Gomez; John Dylewski Journal: Cureus Date: 2021-11-17